A patient has been newly diagnosed with obsessive-compulsive disorder (OCD). The provider is considering starting medication treatment. Which medication is most commonly prescribed as a first-line treatment for OCD?

Choice A reason: Sertraline, an SSRI, increases serotonin in the cortico-striato-thalamo-coral circuit, addressing OCD’s core serotonin deficiency. It reduces orbitofrontal cortex hyperactivity and basal ganglia-driven compulsive loops, alleviating amygdala anxiety. As a first-line treatment, its efficacy is supported by clinical trials, promoting neuroplasticity and symptom reduction in OCD patients. Choice B reason: Lithium stabilizes mood in bipolar disorder by modulating glutamate and GSK3 in the limbic system. OCD’s pathophysiology involves serotonin, not mood cycling, in the basal ganglia. Lithium lacks direct effects on serotonin pathways, making it ineffective for OCD’s obsessive compulsive cycles, despite its role in other psychiatric conditions. Choice C reason: Alprazolam, a benzodiazepine, enhances GABA-A receptor activity, reducing anxiety in the amygdala. OCD is driven by serotonin deficits in cortical-striatal circuits, not GABA imbalances. Alprazolam offers transient anxiety relief but doesn’t address compulsions, risking dependency without impacting long-term neurobiology, making it unsuitable as first-line. Choice D reason: Haloperidol, a typical antipsychotic, blocks dopamine D2 receptors, used in schizophrenia’s psychotic symptoms. OCD involves serotonin dysregulation, not dopamine, in the orbitofrontal cortex. Haloperidol may worsen anxiety or extrapyramidal side effects, with no effect on compulsive behaviors, making it inappropriate for OCD’s first-line treatment.